PC
MNTA

Paulson & Co’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Paulson & Co’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-21,800
Closed -$324K – 104
2015
Q4 		$324K Buy
+21,800
New +$365K ﹤0.01% 74

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Paulson & Co's MNTA Position: Q1 2016 in Review

Paulson & Co sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2016, closing a stake of 21,800 shares — an estimated $324K sold.

Paulson & Co first reported a position in MNTA in Q4 2015 and held it in 1 quarter. The position peaked at $324K in Q4 2015. 148 funds tracked by Wall St. Rank hold MNTA as of Q1 2016.

  • Paulson & Co reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Paulson & Co sold 21,800 Momenta Pharmaceuticals, Inc. shares in Q1 2016, an estimated $324K.
  • Paulson & Co first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • Paulson & Co's Momenta Pharmaceuticals, Inc. position peaked at $324K in Q4 2015.
  • 148 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2016.

Based on Paulson & Co's 13F filing for Q1 2016, filed 16 May 2016.